NCT06987383View on ClinicalTrials.gov

Vibegron - A Novel Treatment for Multisystem Functional Decline in Aging and Obesity

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2026

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2028

Conditions
Obesity
Interventions
DRUG

Vibegron

A drug in a class of medications called beta-3 adrenergic agonists; approved for use with Overactive Bladder; 75mg tablets will be used in this study

DRUG

Placebo

Tablets made of inert substance that looks like the vibegron tablets but has no therapeutic value

Trial Locations (1)

27157

Wake Forest University Health Sciences, Winston-Salem

All Listed Sponsors
lead

Wake Forest University Health Sciences

OTHER